Risuteganib is under clinical development by Allegro Ophthalmics and currently in Phase II for Dry (Atrophic) Macular Degeneration. According to GlobalData, Phase II drugs for Dry (Atrophic) Macular Degeneration does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Risuteganib LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Risuteganib overview

Risuteganib is under development for the treatment of diabetic macular edema, dry age-related macular degeneration and retinitis pigmentosa. The drug candidate is administered as a intravitreal and intraocular injection. The drug candidate is a synthetic anti-integrin oligopeptide. ALG-­1001 works from a different mechanism of action than current anti-­VEGF treatments by binding to multiple integrin-­receptor sites (alpha V, beta 1,3,5) and affecting multiple angiogenic pathways.

It was also under development for the treatment of wet age-related macular degeneration, posterior vitreous detachment in non-proliferative diabetic retinopathy, symptomatic focal vitreomacular adhesion and vitreomacular traction (VMT).

Allegro Ophthalmics overview

Allegro Ophthalmics is an ophthalmic pharmaceutical company. The company uses integrin-regulating therapy for the treatment of vascular eye diseases. Allegro Ophthalmics is headquartered in San Juan Capistrano, California, the US.

For a complete picture of Risuteganib’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.